In vitro and in vivo studies of boron conjugated melanoma affined biochemicals
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Urban & Vogel GmbH
Abstract
The incidence of malignant melanoma (MM) is increasing in caucasians, and in Australia the rate has doubled since the seventies. Queensland has the highest incidence in the world at 33 cases per 100000 people. This increased frequency and poor prognosis for advanced cases has prompted an increased interest in new therapeutic methods. One such method is neutron capture therapy (NCT) which relies on the incorporation of boron compounds in cancer cells.
Most of the NCT experiments reported to date have used the B16 murine [3, 4] and HP hamster [2] melanoma cell lines. In order to provide evidence for the wider application of NCT, we have targeted several human MM cell lines with boron conjugated phenylalianine (BPA) [4] and tetraphenylporphyrin (BTPP) [5]. © Urban & Vogel GmbH
Description
Physical copies held by ANSTO Library at DDC: 616.9440642/30
Citation
Allen, B. J., Brown, J. K., Mountford, M. H., Tamat, S. R., Patwardhan, A., Moore, D. E., Ichihashi, M., Mishima, Y., & Kahl, S. B. (1989). In vitro and in vivo studies of boron conjugated melanoma affined biochemicals. Paper presented to the Third International Symposium on Neutron Capture Therapy, Bremen 31 May-3 June 1988, in Strahlenther und Onkologie, 165(2-3), 163-165.